Orforglipron is a once-daily oral medication for the treatment of obesity and type 2 diabetes.
Trademame Foundayo.
Mechanism: It is a non-peptide, small-molecule GLP-1 receptor agonist.
Unlike many other GLP-1 drugs (like Ozempic or Wegovy), it is not a protein, which allows it to be absorbed through the gut without being destroyed by stomach enzymes.
Administration: It is a pill taken once daily that does not require refrigeration or specific timing with food or water.
It can be taken with or without food.
Weight Loss: In a 72-week study (ATTAIN-1 trial) of adults with obesity but without diabetes, participants taking the highest dose (36 mg) lost an average of 11.2% to 12.4% of their body weight.
In the ACHIEVE-1 trial for type 2 diabetes, orforglipron reduced A1C levels by an average of 1.3% to 1.6% over 40 weeks.
The ATTAIN-MAINTAIN study demonstrated that it could help individuals maintain weight loss after switching from injectable therapies like Zepbound or Wegovy.
Once daily at doses from 6 to 36 mg a day, averaged after 72 weeks a weight loss in the highest dose group at 11%.
Side Effects: The most common side effects are gastrointestinal, such as nausea, vomiting, and diarrhea, which are typically mild to moderate and occur most often during the initial dose-escalation phase.
Can be taken at anytime of day without water or food restrictions.